gms | German Medical Science

83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

16.05. - 20.05.2012, Mainz

microRNA-205 expression and its regulation in laryngeal squamous cell carcinoma

Meeting Abstract

Suche in Medline nach

  • corresponding author Ming Liu - The 2nd Affiliated Hospital of Harbin Medical University, Harbin, P.R. China
  • Linli Tian - The 2nd Affiliated Hospital of Harbin Medical University, Harbin, P.R. China
  • Jiarui Zhang - The 2nd Affiliated Hospital of Harbin Medical University, Harbin, P.R. China
  • Yanan Sun - The 2nd Affiliated Hospital of Harbin Medical University, Harbin, P.R. China

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Mainz, 16.-20.05.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12hnod265

doi: 10.3205/12hnod265, urn:nbn:de:0183-12hnod2653

Veröffentlicht: 4. April 2012

© 2012 Liu et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

MicroRNAs are a class of small noncoding RNA molecules of 22 nucleotides in length that modulate gene expression post-transcriptionally. miR-205 is a highly conserved miRNA among different species, and is repressed in many tumors and cancer cell lines, including head and cancers. By using RT-PCR, we have firstly demonstrated that miR-205 was shown to be down-regulated in the primary laryngeal carcinoma. We next used a plasmid vector system that incorporates GFP as a reporter gene to express hsa-miR-205 to up-regulate miR-205 in Hep-2 cell line. Compared to the control, a high percentage of Hep-2 cells expressed GFP with has-miR-205 plasmid at 48 h after the transfection. MTT assays showed that the cell lines revealed significantly lower percent of surviving cells when treated with hsa-miR-205 plasmid compared to controls at each different time point. Flow-cytometric analysis demonstrated that transfected Hep-2 cells resulted in a significant increase in the percentage of apoptotic cells, compared with the control cells. Interestingly, up-regulation of miR-205 could suppress 2 oncogenes, such as DHFR and Bcl-2 expressions of Hep-2 cell lines, and this suppression was further confirmed immunohistochemically in xenograft tumor. In-vivo experiments showed that a significant growth reduction for the xenograft tumors resulted from Hep-2 cells transfected with has-miR-205 plasmid compared to the controls. Our data demonstrated for the first time that up-regulation of miR-205 could inhibit cell growth and promote apoptosis of Hep-2 cells and because an inverse correlation was found between the expression of miR-205 and DHFR and Bcl-2 oncogenes, miR-205 is probably a promising tumor suppressor.